Want to see HK:2373 full AI Analyst Report?
2373 Stock Chart & Stats
HK$18.90
HK$0.10(0.53%)
At close: 4:00 PM EDT
HK$18.90
HK$0.10(0.53%)
Day’s Range― - ―
52-Week RangeHK$15.60 - HK$41.60
Previous CloseN/A
Volume0.00
Average Volume (3M)539.77K
Market Cap
HK$4.74B
Enterprise ValueHK$4.04B
Total Cash (Recent Filing)HK$2.57B
Total Debt (Recent Filing)HK$1.29B
Price to Earnings (P/E)11.8
Beta0.51
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.75%
Share Statistics
EPS (TTM)1.38
Shares Outstanding251,593,720
10 Day Avg. Volume911,428
30 Day Avg. Volume539,766
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)5.54
Price to Sales (P/S)1.89
P/FCF Ratio6.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$27.65Price Target Upside46.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.86
Revenue Forecast (FY)HK$3.90B
Bulls Say, Bears Say
Bulls Say
Strong Revenue ExpansionSustained revenue expansion through 2023–2025, with a sharp step-up in 2025, indicates improving market traction and service uptake. Durable top-line growth supports scale economies, reinvestment capacity and a higher baseline for future cash flow generation over the next 2–6 months.
Improving Profit MarginsHigher net and gross margins between 2024 and 2025 reflect improved pricing, cost control, or mix shift toward higher-margin services. Margin improvement is a durable fundamental that enhances operating leverage, strengthens free cash flow potential and supports reinvestment or debt service capacity.
Improved Operating Cash GenerationRising operating cash flow and reported free cash flow in 2025 point to better cash conversion and operational efficiency. Strong cash generation underpins capital spending, dividend coverage and deleveraging options, improving financial flexibility over a multi-month horizon.
Bears Say
Sharply Higher LeverageThe jump in debt-to-equity to 1.27 materially raises financial risk and interest burden, reducing balance sheet flexibility. Elevated leverage can constrain capital allocation, increase refinancing sensitivity and magnify downside in a revenue or margin shock over the next several quarters.
Cash-flow Quality UncertaintyDespite positive headline cashflow, reported zero coverage metrics and negative FCF growth signal one-off timing or inconsistent cash quality. This ambiguity reduces confidence in sustainable free cash generation, complicating forecasts and raising refinancing or dividend risk in the medium term.
Earnings And Margin Volatility HistoryNotable EBITDA margin swings and a prior revenue decline (2022) indicate earnings volatility. For a care-facilities business, inconsistency in demand or cost structure can impair predictability of cash flows, making capital planning and credit metrics less reliable across quarters.
Beauty Farm Medical & Health Industry, Inc. News
2373 FAQ
What was Beauty Farm Medical & Health Industry, Inc.’s price range in the past 12 months?
Beauty Farm Medical & Health Industry, Inc. lowest stock price was HK$15.60 and its highest was HK$41.60 in the past 12 months.
What is Beauty Farm Medical & Health Industry, Inc.’s market cap?
Beauty Farm Medical & Health Industry, Inc.’s market cap is HK$4.74B.
When is Beauty Farm Medical & Health Industry, Inc.’s upcoming earnings report date?
Beauty Farm Medical & Health Industry, Inc.’s upcoming earnings report date is Sep 01, 2026 which is in 25 days.
How were Beauty Farm Medical & Health Industry, Inc.’s earnings last quarter?
Beauty Farm Medical & Health Industry, Inc. released its earnings results on Mar 27, 2026. The company reported HK$0.752 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.752.
Is Beauty Farm Medical & Health Industry, Inc. overvalued?
According to Wall Street analysts Beauty Farm Medical & Health Industry, Inc.’s price is currently Undervalued.
Does Beauty Farm Medical & Health Industry, Inc. pay dividends?
Beauty Farm Medical & Health Industry, Inc. pays a Annually dividend of HK$0.72 which represents an annual dividend yield of 2.75%. See more information on Beauty Farm Medical & Health Industry, Inc. dividends here
What is Beauty Farm Medical & Health Industry, Inc.’s EPS estimate?
Beauty Farm Medical & Health Industry, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beauty Farm Medical & Health Industry, Inc. have?
Beauty Farm Medical & Health Industry, Inc. has 251,593,720 shares outstanding.
What happened to Beauty Farm Medical & Health Industry, Inc.’s price movement after its last earnings report?
Beauty Farm Medical & Health Industry, Inc. reported an EPS of HK$0.752 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.147%.
Which hedge fund is a major shareholder of Beauty Farm Medical & Health Industry, Inc.?
Currently, no hedge funds are holding shares in HK:2373
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beauty Farm Medical & Health Industry, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$27.65 (46.30% Upside)
HK$27.65 (46.30% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.26%
12-Months-Change
Fundamentals
Return on Equity
2.75%
Trailing 12-Months
Asset Growth
23.50%
Trailing 12-Months
Company Description
Beauty Farm Medical & Health Industry, Inc.
Beauty Farm Medical and Health Industry Inc., established in 1993 and based in Shanghai, People's Republic of China, delivers comprehensive beauty and health management services across China. Its diverse offerings encompass traditional beauty treatments; advanced aesthetic medical services, including non-surgical options like energy-based therapies and injections, as well as surgical procedures; and specialized subhealth assessment and intervention programs. As of June 30, 2022, the company operated a network of 352 stores under its BeautyFarm, Palaispa, Neology, and CellCare brands, with 177 being directly owned and 175 franchised.
2373 Stock 12 Month Forecast
Average Price Target
HK$27.65
▲(46.30% Upside)
Technical Analysis
Raily Aesthetic Medicine International Holdings Limited
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―
Arrail Group Ltd.
―
UMP Healthcare Holdings Limited
―